FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328124426> ?p ?o ?g. }

• W4328124426 endingPage "962" @default.
• W4328124426 startingPage "962" @default.
• W4328124426 abstract "Objective: The effectiveness and safety of belimumab in Chinese lupus patients with different disease activities were investigated in a real-world setting. Method: Patients who received 10 mg/kg belimumab intravenously on weeks 0, 2, and 4, and then every 4 weeks on a background of standard-of-care (SoC) therapy and had a follow-up of more than 6 months were enrolled from four centers in China. They were stratified according to the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score at baseline as the moderate/severe (SELENA-SLEDAI > 6) or mild subgroups (SELENA-SLEDAI ≤ 6). Attainment of the Lupus Low Disease Activity State (LLDAS) or remission on treatment was analyzed in all patients. The SLE Responder Index 4 (SRI-4) and SELENA-SLEDAI Flare Index (SFI) were evaluated for patients with moderate/severe disease and mild disease, respectively. Patients in the control arm with SoC alone from previous metformin lupus trials were selected by propensity score matching (PSM) as the reference group. Results: 224 SLE patients with a mean follow-up of 11.7 months receiving belimumab were enrolled in this observational study, of which 126 and 98 were in the moderate/severe and mild subgroup, respectively. At 12 months, 54.76% of the patients attained LLDAS and 28.57% attained remission. Lower daily prednisone at baseline were independently associated with 12-month LLDAS. Further, 87% of the subgroup with moderate/severe disease achieved SRI-4 at 12 months and a high SLEDAI at baseline was its predictive factor. For the mild subgroup, a reduced flare rate was observed compared with PSM reference (17.5%, vs. 38.6%, p = 0.021). Infection events, particularly viral infections and pneumonia were recorded in 7 and 6 patients, respectively. Conclusion: Our real-world data supported the effectiveness and safety of belimumab in Chinese lupus patients." @default.
• W4328124426 created "2023-03-22" @default.
• W4328124426 creator A5005209825 @default.
• W4328124426 creator A5009169961 @default.
• W4328124426 creator A5010479652 @default.
• W4328124426 creator A5012285468 @default.
• W4328124426 creator A5022533710 @default.
• W4328124426 creator A5028878852 @default.
• W4328124426 creator A5034417510 @default.
• W4328124426 creator A5039687656 @default.
• W4328124426 creator A5064836722 @default.
• W4328124426 creator A5065034639 @default.
• W4328124426 creator A5065582525 @default.
• W4328124426 creator A5082293139 @default.
• W4328124426 date "2023-03-21" @default.
• W4328124426 modified "2023-10-10" @default.
• W4328124426 title "Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study" @default.
• W4328124426 cites W1975085076 @default.
• W4328124426 cites W2070527591 @default.
• W4328124426 cites W2105253459 @default.
• W4328124426 cites W2108905161 @default.
• W4328124426 cites W2119296184 @default.
• W4328124426 cites W2131457901 @default.
• W4328124426 cites W2136149088 @default.
• W4328124426 cites W2141455950 @default.
• W4328124426 cites W2184068658 @default.
• W4328124426 cites W2199189793 @default.
• W4328124426 cites W2255119417 @default.
• W4328124426 cites W2549269809 @default.
• W4328124426 cites W2587800318 @default.
• W4328124426 cites W2739431617 @default.
• W4328124426 cites W2756377741 @default.
• W4328124426 cites W2782542157 @default.
• W4328124426 cites W2904663386 @default.
• W4328124426 cites W2907178835 @default.
• W4328124426 cites W2912932678 @default.
• W4328124426 cites W2922079909 @default.
• W4328124426 cites W2927871970 @default.
• W4328124426 cites W3008726116 @default.
• W4328124426 cites W3015211672 @default.
• W4328124426 cites W4210541409 @default.
• W4328124426 doi "https://doi.org/10.3390/biomedicines11030962" @default.
• W4328124426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36979944" @default.
• W4328124426 hasPublicationYear "2023" @default.
• W4328124426 type Work @default.
• W4328124426 citedByCount "1" @default.
• W4328124426 crossrefType "journal-article" @default.
• W4328124426 hasAuthorship W4328124426A5005209825 @default.
• W4328124426 hasAuthorship W4328124426A5009169961 @default.
• W4328124426 hasAuthorship W4328124426A5010479652 @default.
• W4328124426 hasAuthorship W4328124426A5012285468 @default.
• W4328124426 hasAuthorship W4328124426A5022533710 @default.
• W4328124426 hasAuthorship W4328124426A5028878852 @default.
• W4328124426 hasAuthorship W4328124426A5034417510 @default.
• W4328124426 hasAuthorship W4328124426A5039687656 @default.
• W4328124426 hasAuthorship W4328124426A5064836722 @default.
• W4328124426 hasAuthorship W4328124426A5065034639 @default.
• W4328124426 hasAuthorship W4328124426A5065582525 @default.
• W4328124426 hasAuthorship W4328124426A5082293139 @default.
• W4328124426 hasBestOaLocation W43281244261 @default.
• W4328124426 hasConcept C126322002 @default.
• W4328124426 hasConcept C159654299 @default.
• W4328124426 hasConcept C170286685 @default.
• W4328124426 hasConcept C1862650 @default.
• W4328124426 hasConcept C187960798 @default.
• W4328124426 hasConcept C197934379 @default.
• W4328124426 hasConcept C203014093 @default.
• W4328124426 hasConcept C23131810 @default.
• W4328124426 hasConcept C2775915377 @default.
• W4328124426 hasConcept C2776912625 @default.
• W4328124426 hasConcept C2778453870 @default.
• W4328124426 hasConcept C2778720950 @default.
• W4328124426 hasConcept C2779134260 @default.
• W4328124426 hasConcept C2779912601 @default.
• W4328124426 hasConcept C2781205201 @default.
• W4328124426 hasConcept C44249647 @default.
• W4328124426 hasConcept C71924100 @default.
• W4328124426 hasConceptScore W4328124426C126322002 @default.
• W4328124426 hasConceptScore W4328124426C159654299 @default.
• W4328124426 hasConceptScore W4328124426C170286685 @default.
• W4328124426 hasConceptScore W4328124426C1862650 @default.
• W4328124426 hasConceptScore W4328124426C187960798 @default.
• W4328124426 hasConceptScore W4328124426C197934379 @default.
• W4328124426 hasConceptScore W4328124426C203014093 @default.
• W4328124426 hasConceptScore W4328124426C23131810 @default.
• W4328124426 hasConceptScore W4328124426C2775915377 @default.
• W4328124426 hasConceptScore W4328124426C2776912625 @default.
• W4328124426 hasConceptScore W4328124426C2778453870 @default.
• W4328124426 hasConceptScore W4328124426C2778720950 @default.
• W4328124426 hasConceptScore W4328124426C2779134260 @default.
• W4328124426 hasConceptScore W4328124426C2779912601 @default.
• W4328124426 hasConceptScore W4328124426C2781205201 @default.
• W4328124426 hasConceptScore W4328124426C44249647 @default.
• W4328124426 hasConceptScore W4328124426C71924100 @default.
• W4328124426 hasFunder F4320317789 @default.
• W4328124426 hasFunder F4320325338 @default.
• W4328124426 hasIssue "3" @default.
• W4328124426 hasLocation W43281244261 @default.

• next